Most comprehensive ADC conference dedicated to Asia-Pacific—where decision-makers gather to exchange ideas, celebrate excellence, explore opportunities, and drive business deals

Dr. Paul Song has nearly 30 years of expertise in biotherapeutics drug discovery and development, specializing in immunology and oncology. He is currently the Chief Scientific Officer at GeneQuantum Healthcare in Suzhou, China, where he leads R&D, including new ADC target discovery and the advancement of an innovative bioconjugate pipelines. Dr. Song has been instrumental in establishing GeneQuantum as a global leader in ADCs through cutting-edge technologies.

Previously, he co-founded Curon Bio in Shanghai, China, a biotech venture focused on next-generation immuno-oncology therapeutics, and served as its CSO, laying a strong foundation for the company's rapid growth. He also served as Vice President at Samsung Bioepis in Seoul, Korea, playing a pivotal role in establishing the company as a global leader in biosimilars. Earlier, he was a Principal Research Scientist at Lilly Research Laboratories in Indianapolis, USA. Dr. Song holds a Ph.D. in Biology from Purdue University, USA.

Dr. Heidi Wang is an experienced global drug development and regulatory expert with 30+ years of Pharmaceutical Industry and Biotech experience. With expertise in Oncology, Virology, Immunology, and other therapeutic areas, Heidi led and contributed to shaping strategy and delivering approvals for Bristol Myers Squibb Company (BMS) and now, for OBI Pharma. Importantly, Heidi’s positive leadership style and inclusive mindset helped to transform both company’s culture and processes to optimize their portfolio acceleration and to bring people together. Leveraging her strengths in problem solving, risk mitigation, and asking the right questions, coupled with a deep expertise in drug development, Heidi is now guiding OBI Pharma and as a Board member of 2 companies and her alma mater, Fu-Jen University. She volunteers as an advisor and mentor to individuals and multiple organizations in the US, Europe, and Taiwan

Ben is the Vice President of Antibody-Drug Conjugates at Hummingbird Bioscience. With more than 16 years’ experience in the biopharma sector, Ben leads the strategy and development of the Antibody-Drug Conjugates platform and programs at Hummingbird Bioscience. Ben also held strategy and preclinical roles since joining Hummingbird Bioscience in 2020.

Prior to joining Hummingbird Bioscience, Ben advised companies on commercial strategy in APAC at ZS Associates, a healthcare-focused management consulting firm. Ben has accumulated a decade of experience in medicinal chemistry research in a wide range of therapeutic areas including oncology, tropical disease, diabetes, cystic fibrosis, and lysosomal storage diseases at Novartis, the Institute of Cancer Research, and the University of Oxford.

Ben holds a M.Chem. in Chemistry and a D.Phil in Organic Chemistry from the University of Oxford.

Dr. Chuang received his PhD degree in Medicinal Chemistry from National Tsing Hua University. As a principal investigator in Development Center for Biotechnology (DCB), he led several drug discovery projects especially on oncology field. These topics include Top1 inhibitor, Nek2/Hec1 inhibitor, antibody-drug conjugates (ADC) and proteolysis targeting chimera (PROTAC). After more than 15 years, he left DCB and joined OBI Pharma as the director of Medicinal Chemistry and focusing on developing anti-Trop2 ADC. In 2022, Dr. Chuang co-founded HoneyBear Biosciences, and serve as the CEO.

Zou Bin is a seasoned executive and has helmed many leadership positions. He is currently an Adjunct Associate Professor at National University of Singapore. Previously, he served as Managing Director at Trinity Innovation Bioventure Singapore (TIBS) and was the CEO of Shanghai Blueray Biopharma where he successfully led the team to develop several candidates into clinic stage. Prior to his venture, Dr. Zou was a Principal Scientist at Novartis Institute for Tropical Disease where he spearheaded the team to the discovery of Phase II clinical trials drug NITD609. He is the author to more than 25 peer reviewed publications.